Literature DB >> 34304250

DIF-1 inhibits growth and metastasis of triple-negative breast cancer through AMPK-mediated inhibition of the mTORC1-S6K signaling pathway.

Fumi Seto-Tetsuo1, Masaki Arioka2, Koichi Miura1, Takeru Inoue1, Kazunobu Igawa3, Katsuhiko Tomooka3, Fumi Takahashi-Yanaga4, Toshiyuki Sasaguri5.   

Abstract

We have previously reported that the differentiation-inducing factor-1 (DIF-1), a compound identified in Dictyostelium discoideum, suppresses the growth of MCF-7 breast cancer cells by inactivating p70 ribosomal protein S6 kinase (p70S6K). Therefore, we first examined whether the same mechanism operates in other breast cancer cells, especially triple-negative breast cancer (TNBC), the most aggressive and refractory phenotype of breast cancer. We also investigated the mechanism by which DIF-1 suppresses p70S6K by focusing on the AMPK-mTORC1 system. We found that DIF-1 induces phosphorylation of AMPK and Raptor and dephosphorylation of p70S6K in multiple TNBC cell lines. Next, we examined whether AMPK-mediated inhibition of p70S6K leads to the suppression of proliferation and migration/infiltration of TNBC cells. DIF-1 significantly reduced the expression levels of cyclin D1 by suppressing the translation of STAT3 and strongly suppressed the expression levels of Snail, which led to the suppression of growth and motility, respectively. Finally, we investigated whether DIF-1 exerts anticancer effects on TNBC in vivo. Intragastric administration of DIF-1 suppressed tumor growth and spontaneous lung metastasis of 4T1-Luc cells injected into the mammary fat pad of BALB/c mice. DIF-1 is expected to lead to the development of anticancer drugs, including anti-TNBC, by a novel mechanism.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34304250     DOI: 10.1038/s41388-021-01958-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.

Authors:  Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-10-29       Impact factor: 508.702

Review 2.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

3.  Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum.

Authors:  H R Morris; G W Taylor; M S Masento; K A Jermyn; R R Kay
Journal:  Nature       Date:  1987 Aug 27-Sep 2       Impact factor: 49.962

Review 4.  Genetic susceptibility to triple-negative breast cancer.

Authors:  Kristen N Stevens; Celine M Vachon; Fergus J Couch
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

5.  Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.

Authors:  Lu Chen; Hannah M Linden; Benjamin O Anderson; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2014-08-28       Impact factor: 4.872

Review 6.  Triple-negative breast cancer: is there a treatment on the horizon?

Authors:  Hui Yao; Guangchun He; Shichao Yan; Chao Chen; Liujiang Song; Thomas J Rosol; Xiyun Deng
Journal:  Oncotarget       Date:  2017-01-03

7.  Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project.

Authors:  Koshi Nakamura; Emiko Okada; Shigekazu Ukawa; Makoto Hirata; Akiko Nagai; Zentaro Yamagata; Yutaka Kiyohara; Kaori Muto; Yoichiro Kamatani; Toshiharu Ninomiya; Koichi Matsuda; Michiaki Kubo; Yusuke Nakamura; Akiko Tamakoshi
Journal:  J Epidemiol       Date:  2017-02-20       Impact factor: 3.211

8.  Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women.

Authors:  Sandra Diaz Casas; Eder Lancheros García; Andrés Sanchéz Campo; Ricardo Sanchez Pedraza; Vivian Roman Vasquez; Sara D Mendoza; Javier Angel Aristizabal; Carlos Lehmann Mosquera; Carlos Duarte Torres; Juan C Vergel
Journal:  Cureus       Date:  2019-06-21

9.  Differentiation-inducing factor-1 suppresses cyclin D1-induced cell proliferation of MCF-7 breast cancer cells by inhibiting S6K-mediated signal transducer and activator of transcription 3 synthesis.

Authors:  Fumi Tetsuo; Masaki Arioka; Koichi Miura; Misato Kai; Momoko Kubo; Kazunobu Igawa; Katsuhiko Tomooka; Fumi Takahashi-Yanaga; Fusanori Nishimura; Toshiyuki Sasaguri
Journal:  Cancer Sci       Date:  2019-10-26       Impact factor: 6.716

Review 10.  Triple-negative breast cancer molecular subtyping and treatment progress.

Authors:  Li Yin; Jiang-Jie Duan; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Breast Cancer Res       Date:  2020-06-09       Impact factor: 6.466

View more
  3 in total

Review 1.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 2.  Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights.

Authors:  Bhawna Uprety; Heidi Abrahamse
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

3.  Autophagy regulated by the HIF/REDD1/mTORC1 signaling is progressively increased during erythroid differentiation under hypoxia.

Authors:  Jian Li; Cheng Quan; Yun-Ling He; Yan Cao; Ying Chen; Yu-Fei Wang; Li-Ying Wu
Journal:  Front Cell Dev Biol       Date:  2022-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.